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There is conflicting evidence about the relative roles of division and "re- 
cruitment" of responding  ceils during  the  early primary immune response. 
The cells primarily releasing "19S" hemolysin for sheep erythrocytes may be 
enumerated using the plaque-forming cell technique developed by Jeme and 
Nordin (1, 2) and independently by Ingraham (3).  An exponential increase in 
plaque-forming cells occurs during the early primary response; doubling times 
vary from about 5 to 10 hr depending on the dose of antigen and other experi- 
mental variables (4-14). 
A method using mitotic blocking agents to estimate cell cycle times of anti- 
body-formlng cells, in vivo and in vitro, is presented. Results with this method 
indicate that the increase in numbers of antibody-forming cells which occurs 
during the early primary response is due primarily to exponential division of 
responding  cells.  Increased  responses  produced  by  larger  antigen  doses  or 
adjuvant appear  to  result from an increased rate  of division of responding 
cells.  These findings are  contrary to the view that the observed increase in 
antibody-producing ceils can be attributed to continued activation or recruit- 
ment of potential antibody-producing cells (9-14). 
Materials and Methods 
Young adult Sprague Dawley  rats were used. The antigen was washed whole  erythrocytes 
prepared from sterile sheep's blood. A single sample of blood stored in Alsever's  solution  was 
used in each experiment both for ;mmunization  and for titrating immune respo~es. The 
sheep erythroc~es were washed four times in large volumes of freshly prepared pyrogen- 
free saline and used immediately. Doses of sheep erythrocytes were standardized by ceil 
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count. Bordetella pert~ssis vaccine was used to enhance the response to sheep erythrocytes 
and will be referred to as adjuvant. The vaccine (Lilly, strain 37790, lot T-59187),  containing 
about 50 opacity units per ml and Merthiolate 1:10,000,  was kindly supplied through Dr. H. 
Campbell, Jr., Biological Development, Eli Lilly and Co., Indianapolis, Ind. The adjuvant 
was mixed with antigen or injected separately as indicated. All injections of antigen and adju- 
vant were into the lateral tail vein. 
Plaque-Forming Ce//s.--The method of Jerne and Nordin  (1) for demonstrating release of 
antibody by single cells in agar plates was used with minor modifications (15).  Each spleen 
was minced and passed through a wire gauze screen using a pestle and 4.0 ml of tissue culture 
medium. Repeated pipetting of the cell suspension caused additional dispersion of cells. The 
volume of the suspension was brought to 5.0 ml and tissue fragments were removed by low 
speed centrifugation for 30 sec. 0.1 ml of an appropriate dilution of the spleen cell suspension 
and 0.1 ml of a suspension  containing 2 X  10  s sheep erythrocytes mixed with 2.0 ml of agar- 
tissue culture medium were layered over a  thin bottom layer of solidified agar-tissue culture 
medium in plastic Petri plates 9.0 cm in diameter. The plates were incubated 1.5 hr at 37°C; 
2.0 ml of normal rat serum diluted 1:3 with saline was added as complement; the plates were 
incubated 1.5 hr at 37°C, washed, and counted immediately. Except for very early responses 
when spleens contained few plaque-forming cells,  the total number of spleen plaque-forming 
cells for each animal was calculated from counts on duplicate plates using dilutions of spleen 
cell suspensions which gave about  100-250  plaques per plate. 
The calculated total number of plaque-forming cells per spleen was transformed by taking 
the logarithm of the number to the base 10. Where means are recorded untransformed, they 
represent the antilog of the mean of the logarithmically tmusformed data. All statistical cal- 
culatious were performed on the logarithmically transformed data. The reasons for preferring 
the logarithmlc to the simple arithmetic seale arise from the fact that the scatter around the 
untransformed  means was grossly dependent upon the mean itself, the higher mean values 
being attended by greater variability. Logarithmic transfornmtion of the data fully corrected 
this feature, so that  th'e variance at different response leveis was independent of the mean 
and showed no significant trend. 
Anffbody T/ters.--Titrations for hemolytic and agglutinating antibody to sheep erythro- 
cytes used the double dilution technique with an initial serum dilution of 1:10 (15, 16). Dur- 
ing the first 5 days of the primary response to sheep erythrocytes, the agglutinin and hemoly- 
sin titers were equal -4- one serum dilution using selected end points; the relationship between 
spleen plaque-forming cells and antibody titers was the same whether agglutinin or hemolysin 
titers were used. Only hemagglutinin titers are reported. For convenience in comparing the 
plaque-forming cell and antibody responses,  titers were also transformed by taking the loga- 
rithm of the number to the base 10.  Where mean titers are recorded untrausformed,  they 
represent the antilog of the mean of the logarithmically transformed data. All statistical cal- 
culatious were performed on the logarithmically transformed  data.  Sera were also titrated 
for antibody not inactivated by 2-mereaptoethanol; serum diluted  1:5 in saline was added 
to an equal volume of 0.1 ~r 2-mercaptoethanol, incubated at 37°C for 30 rain, and then ti- 
trated for hemagglutin~n-q. 
M#.oti¢ Blocking Agents.--Colchieine, 0.5  mg/ml,  injectable,  was  purchased  from  Ell 
Lilly & Co. Velban (vinblastine sulfate) lot No. 9EP95, was kindly supplied by Dr. I. S. John- 
son, Biology Research Division, Eli Lilly & Co.; fresh solutions of the powder dissolved in 
pyrogen-free normal  saline were prepared  for  each experiment. 
In  Vi~ro Cu/tures.--Dispersed spleen ceils of DBA/2 Jax mice were immunized in vitro 
with sheep erythrocytes by the methods of Mishell and Dutton (17, 18) or a modifieation of 
the method used in this laboratory (19). Responses were measured after 1 to 4 days of culture. 
Cultured cells, including cells free in the culture medium and cells adherent to plastic, were 
harvested by scraping dishes with a plastic policeman. A modification of the Jeme technique ~o' 
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using microscopic slides was used for enumerating plaques (18). When responses were meaS- 
ured 4  days after immunization, appropriate  dilutions of cultured cells were made so tlmt 
about  100-200  plaques were present on each slide. Each plaque count recorded for the in 
vitro cultures is the mean (to the nearest whole number) of counts on 2-4 slides prepared from 
a pool obtained from duplicate culture dishes. Counts are expressed as the number of plaques 
or plaque-forming cells per 106 cells initially cultured  (19).  4 day cultures of normal mouse 
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TFJ~-FIO. 1. Spleen plaque-forming cell and serum antibody responses of rats imm.nlzed 
intravenously with 5 X  l0  T, 109 sheep erythrocytes, or 109 sheep erythrocytes and adjuvant. 
The adjuvant was 0.15 ml of B. per~sis vaccine given intravenously at the time of imrmmiza- 
tion. Each point represents the mean of the logx0 transformed data 4- the standard error of 
the mean plotted as a vertical bar. The point at day 0 is the mean for 35 lmlmmunized rats; 
the point at day 1 is the mean for 32 rats; 8 immunized with 5 X  l0  T sheep erythrocytes, 16 
immlmi1~d with 10  9 sheep erythrocytes, and 8 ;mmLl~ed with 10 9 sheep erythrocytes and 
adjuvant. Each other point is the mean for 14 or more rats. 
spleen cells that were not immunized in vitro with sheep erythrocytes had one or fewer "back- 
ground" plaque-forming cells per 10  6 spleen cells initially cultured. 
PR.ELIMINARY OBSERVATIONS 
Responses to Antigen.--The spleen plaque-forming cell and serum antibody 
responses were measured  1-5  days after immunization for doses of antigen 
ranging from 10 ~ to  101  ° sheep erythrocytes per rat.  Spleens of normal rats 
contained about 80 "background" plaque-forming cells for sheep erythrocytes; 
sera contained no detectable antibody to the antigen. Rats immunized with 986  ANTIBODY-I~ORMING  CELLS  AND  EARLY  IMMUNE  RESPONSE 
106-10  ~ sheep erythrocytes invariably had slightly increased numbers of spleen 
plaque-formlng cells by 3-5 days; there was considerable individual variation 
in response, and sera contained no or very low titers of antibody. A  dose of 
5  X  10  T sheep  erythrocytes approximated the  lowest  dose of  antigen  that 
regularly produced  reasonably consistent  plaque-forming  cell  and  antibody 
responses. Maximum responses were produced by 5  X  10s-109 sheep erythro- 
cytes; increasing the dose to 10  ~° sheep erythrocytes did not appreciably affect 
the response during the first 5 days. A dose of 10  ~ sheep erythrocytes was se- 
lected as a  "saturation"  dose of antigen,  i.e., a  dose capable of producing a 
maximum response. 
TABLE I 
Adju~ant Enkanr,  ement of Responses to 10  9 Sheep Erytkrocytes 
10  9 SRBC -b adjuvant 
10  9 SRBC 
Difference~ 
Enhancement§ 
Plaque-formlng cells per spleen* 
mean of logx0 -4-sz 
Day 3 
5.08 
±0.04 
4.22 
±0.04 
0.86 
7X 
Day 4 
6.26 
±0.04 
5.12 
±0.05 
1.14 
14 X 
Day 5 
6.33 
±0.04 
5.19 
4-0.08 
1.14 
14 × 
Serum antibody titers* 
mean of 1oglo -4- SE 
Day 3 
1.94 
±0.17 
1.32 
±0.09 
0.62 
4X 
Day 4  Day 5 
3.33  3.66 
±0.11  -4-0.O6 
2.54  2.99 
±0.06  ±0.06 
0.79  0.67 
6X  5X 
* Each mean is for 14 or more rats. 
The difference  equals the mean for spleen plaque-forming  cells or antibody titers of rats 
immunized with antigen and adjuvant minus the mean for animals immunized with antigen 
alone. 
§ Enhancement equals the antilog of the difference. 
In repeated experiments, rats were injected with 5 X  10  T  or 109 sheep erythro- 
cytes and killed 1-5 days after immunization. The results have been combined 
and plotted on Text-fig. 1.  1 day after immunization,  spleen plaque-forming 
ceils were slightly increased above background.  Between days  1  and 4,  the 
increase in plaque-forming cells was exponential for both doses of antigen, but 
the  rate  of increase was higher for the larger dose of antigen.  The average 
doubling time of plaque-forming cells from days 1 to 4 was 8.3 hr for the lower 
dose and 6.9 hr for the higher dose of antigen. The number of plaque-forming 
cells increased slightly from the 4th to the 5th day. The rise in serum titer from 
days 3  to 5  correlated reasonably well with the rise in plaque-forming cells. 
All measurable antibody on days 3, 4, and 5 was inactivated by 2-mercapto- 
ethanol. 
Responses  to Antigen  c~nd Adjuvant.--The  adjuvant effect of various doses ROWLEY~ ~ITCH~ MOSIER~ SOLLIDAY~ COPPLESON~ BROWN  987 
of pertussis vaccine was measured using 10 9 sheep erythrocytes, i.e., a "satura- 
tion" dose of antigen. Doses of 0.4 ml or more of adjuvant produced death or 
severe weight loss, and therefore were not used. Doses of 0.2 or 0.1 ml of ad- 
juvant produced equal enhancement. Decreasing the dose of adjuvant to 0.01 
ml reduced enhancement by about one half. On the basis of these findings, a 
dose of 0.15 ml of adjuvant was arbitrarily selected as capable of producing 
maximum enhancement, and this dose was used for all subsequent experiments. 
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TExT-FIo. 2. Enhancement of the spleen plaque-forming cell response by adjuvant, 0.15 
ml of B. pertussis vaccine, given 1 day after immunization  with 10  9 sheep erythrocytes. Each 
point represents the mean of the log10 transformed data 4- the standard error of the mean 
plotted as a vertical bar. The point at day 1 is the mean for 8 rats;  each other point is 
the mean for 6 rats. 
Enhancement was equivalent whether this dose of adjuvant was mixed with 
the antigen in vitro or was injected separately at the time of immunization. 
In repeated experiments, rats were injected with 10  9 sheep erythrocytes and 
0.15 ml of adjuvant and were killed 1-5 days after immunization. The results 
have been combined and plotted on Text-fig. 1. 1 day after antigen and adju- 
vant,  spleen plaque-forming cells were slightly increased  above background 
but were equal in number to those detected after immunization with 5 X  l0  T 
or 10  9 sheep erythrocytes alone. Between days 1 and 4, the increase in plaque- 
forming cells was  exponential with an average doubling time of 5.2 hr.  The 
number of plaque-forming cells increased slightly from the 4th to the 5th day. 988  ANTIBODY-FORMING CELLS  AND  EARLY  IMMUNE  RESPONSE 
The rise in serum fiter from days 3  to 5  correlated well with the increase in 
plaque-forming cells.  Antibody present  before the  5th  day was  inactivated 
by 2-mercaptoethanol. On the 5th day, low titers of antibody not inactivated 
by 2-mercaptoethanol were  present  in  the  sera.  Adjuvant  enhancement  of 
the  responses  to  109  sheep  erythrocytes is  summarized  in  Table  I.  Plaque- 
forming cell responses were enhanced to a greater extent than antibody titers; 
this discrepancy between the responses will be discussed later. 
TABLE II 
Colckicine Suppression of Spleen Plaque-Forming  Cells on the Third Day of the Primary Response 
Immunization 
5 X l0  T  SRBC 
10  9 SRBC +  adjuvant 
Colchl- I 
clne 
treat- 
ment* 
/sr 
None 
2.5 
5.0 
7.0 
None 
2.S 
5.0 
7.0 
Plsque-forming cells per spleen~ 
Day 2 
569 
(2.76  4- 0.05) 
3230 
(3.51 -4- 0.12) 
Day 3 
5,860 
(3.77 4- o.15) 
3,850 
(3.58 4-  0.24) 
864 
(2.94  .4- 0.26) 
311 
(2.49  .4- 0.17) 
118,150 
(5.07 4- 0.10) 
55,830 
(4.75 4- 0.10) 
11,640 
(4.07  4- 0.26) 
7,670 
(3.88 4-  0.04) 
Day 4 
20,790 
(4.32  4-  0.07) 
965,470 
(5.98 ±  0.12) 
* Rats treated with colchicine  on the 3rd day after immunization received the drug, 1.3 
mg/kg 2.5, 5.0 or 7.0 hr before sacrifice. 
:~ The number of plaque-forming  cells per spleen is the antilog of the mean for 5 rats; the 
log of the mean for 5 rats 4- the standard error of the mean is given in parentheses. 
Controls for experiments using  adjuvant  included rats  injected with 0.15 
ml of adjuvant but no sheep erythrocytes. The animals were killed 1-8 days 
later.  Such rats had from 200 to 2000  "background" spleen plaque-formlng 
cells,  the  greatest  increase  occurring 3  or 4  days  after animals  were given 
adjuvant.  By 8  days,  spleens again contained usual numbers  of background 
plaque-forming cells.  Sera from rats receiving only adjuvant had no measur- 
able antibody to sheep erythrocytes. Adjuvant given alone increased the number 
of background plaques; however, adjuvant given 1, 2, 3, or 4 days before antigen 
did not enhance the response. In contrast, adjuvant given after antigen caused ROWLEY, FITCH,  MOSIER, SOLLIDAY, COPPLESON, BROWN  989 
enhancement of responses as shown in the following experiment. Each of 44 
rats was injected with 109 sheep erythrocytes. 24 hr after immunization, 8 rats 
were  sacrificed for  spleen  plaque-forming  cell determinations;  18  rats  were 
injected with 0.15 ml of adjuvant, and the remaining  18 rats served as con- 
trois.  Groups of 6 rats that received antigen alone and groups of 6 rats that 
received adjuvant 1 day after immunization were killed 2, 3, and 4 days after 
immunization. The spleen plaque-forming ceil responses are plotted on Text- 
fig. 2. Adjuvant enhancement was measurable 2 days after immunization, i.e., 
1 day after adjuvant was given; the response was exponential from days 1 to 4. 
TABLE  HI 
Comparison of Cell Cyde and Cell Doubling Times (See Table II) 
Immunization 
5 X l0  T  SRBC 
10  9 SRBC "4- adjuvant 
Colchidne 
treatment 
/tr 
2.5 
5.0 
7.0 
2.5 
5.0 
7.0 
Cell cycle time* 
Day 3 
/st 
9.2 
6.2 
7.6 
5.7 
5.8 
7.7 
Mean cell cycle 
time~ 
Day 3 
~f 
7.7 
6.4 
Mean ceH doublin 
time~ 
Day 2--4 
9.2 
5.8 
* Cell cycle time is estimated from the extent of colchicine  suppression of plaque-forming 
cells using the method outlined in the Appendix. 
Mean of the estimates for the three time intervals. 
§ Cell doubling time is estimated from numbers of plaque-forming cells present in the 
spleens of noncolchicine  treated immunized rats on days 2, 3 and 4. Method of calculation  is 
outlined in the Appendix. 
Enhancement was almost as great as when adjuvant was given with antigen, 
as may be seen by comparing the responses of adjuvant treated animals in 
Text-figs. 1 and 2. 
EXPERIMENTAL  OBSERVATIONS 
A mitotic blocking agent could be used to estimate in vivo cell cycle times of 
plaque-forming ceils providing that the blocking agent did not inhibit release 
of antibody by ceils during interphase, and that cells blocked in mitosis did 
not release sufficient antibody to be identified. Under these conditions, treat- 
ment of immunized animals with a mitotic blocking agent would render plaque- 
forming ceils undetectable only as the ceils entered mitosis. The reduction in 
numbers of plaque-forming cells would be directly proportional to the length of 
drug treatment, as long as the interval was less than the mean cycle time Of 990  ANTIBODY-FORMING  CELLS  AND  EARLY  IM'M'UN'E RESPONSE 
plaque-forming cells. Cell cycle times could be calculated using a mathematical 
model appropriate for exponentially increasing populations of cells, as described 
in  the Appendix.  The following  experiments demonstrate the use of mitotic 
blocking agents for estimating cell cycle times in this way. 
Use of Mitotic Blocking Agents to Estimate In Vivo Cell Cycle Times of Plaque- 
Forming Cells.--Colchicine or Velban given to immunized rats at various times 
before sacrifice caused reduction in numbers of plaque-forming cells recovered 
from spleens. The extent of reduction was dependent on the dose of the drug, 
the method of immunization, and the interval between drug administration and 
TABLE IV 
Colckir,  ins Suppression of Spleen Plaque-Forming Cells on the Second, 
Third  amt Fourth Days of the Primary Response 
Immunization 
5 X  107 SRBC 
10  ° SRBC -}- adjuvant 
Colchi- 
cine 
treat- 
ment* 
None 
None 
Plaque-forming cells per spleen~ 
Day 2  Day 3  Day 4 
825 
(2.92  4- 0.11) 
249 
(2.40 4- O.O6) 
2971 
(3.4/  4- 0.11) 
296 
(2.47  4- 0.21) 
2,099 
(3.22  -4- 0.08) 
909 
(2.96  4- 0.13) 
113,733 
(S.O6 ±  0.O6) 
8,414 
(3.92  4- 0.08) 
35,800 
(4.55  4- 0.06) 
9,952 
(4.00  4- 0.19) 
1,178,995 
(6.22  4- 0.06) 
103,886 
(5.02 4- 0.10) 
* Rats treated with colchicine received 1.3 nag of drug per kg body weight 5 hr before 
sacrifice. 
~: The number of plaque-forming cells per spleen is the antilog of the mean for 5 rats; the 
log of the mean for 5 rats 4- the standard error of the mean is given in parentheses. 
sacrifice. These parameters of the phenomenon were examined in a large series 
of experiments. Doses of drugs selected for experiments reported here were: 
colchicine  1.3 mg/kg or Velban 3.0 mg/kg. The drugs at these doses produced 
equal effects and could be used interchangeably; reducing either drug dose by 
one third caused significantly  less effect, but increasing  the dose 3-fold caused 
no greater effect than the doses selected.  The extent of suppression of spleen 
plaque-forming ceils was dependent on the duration  of treatment  of animals 
with the blocking agent. For example,  3 days after immunization with 5 X  107 
sheep erythrocytes, five rats received no injections and groups of five rats were 
injected with Velban,  3 mg/kg,  either  4  or 8  hr before sacrifice.  The mean 
numbers of spleen plaque-forming cells were: untreated,  5896  (3.77 4-  0.13); ROWLEY, ~ITCH, MOSIER, SOLLIDAY~ COPPLESON~  BROWN  991 
Velban treatment for 4 hr, 4621 (3.67 -4- 0.19); and Velban treatment for 8 hr. 
2706 (3.43 -4- 0.11)3 
The  extent of drug  suppression was also dependent  on the  immunization 
procedure as well as the duration  of treatment with the blocking agent.  For 
example, 3 days after immunization with 109 sheep erythrocytes and adjuvant, 
five rats received no injections and groups of five rats were injected with Velban, 
3.0 mg/kg, either 3 or 5 hr before sacrifice. The mean number of spleen plaque- 
forming cells were: untreated, 240,932 (5.38 -4- 0.06), Velban treatment for 3 
hr, 50,100 (4.70 -4- 0.06); and Velban treatment for 5 hr, 21,215 (4.33 -4- 0.08). 
In another experiment, 24 rats were irnmuniT~l with 10  ~ sheep erythrocytes; 24 
hr after immunization,  12 rats were injected with adjuvant. 3 days after ira- 
TABLE V 
Compadso, of Cell Cyde and Cell Doubling Times (See Table IV) 
Immunization 
5 X  l0  T SRBC 
10  9 SRBC +  adjuvant 
Colchldne 
treatment 
5 
5 
Cell cycle time* 
Day 2  Day 3  Day 4 
hr  hr  /w 
8.1  10.4  7.7 
5.8  5.6  5.5 
'Mean Cell 
Cycle Time~: 
Day 2-4 
8.7 
5.6 
Mean cell 
doubling time 
Day 2--4 
/w 
8.5 
5.2 
* Cell cycle time is estimated from the extent of colchicine suppression of plaque-forming 
cells using the method outlined in the Appendix. 
Mean of the estimates for the 3 days. 
§ Cell doubling time is estimated from the numbers of plaque-forming cells present in the 
spleens of noncolchlcine treated irnmttnised rats on days 2, 3, and 4. The method of calcula- 
tion is outlined in the Appendix. 
munization, 6 rats in each group were injected with colchicine,  1.3 mg/kg, 5 hr 
before sacrifice. Drug treatment reduced the number of spleen plaque-forming 
cells from 7406 (3.87 -4- 0.09)  to 3980 (3.60 -4- 0.12)  in rats immunized with 
antigen alone, while reduction was from 22,402 (4.35 -4- 0.09) to 1456 (3.16 -4- 
0.12)  in rats that received adjuvant 24 hr after immunization.  Thus,  the ex- 
tent of suppression produced per hour of drug treatment was greater in animals 
having more rapid doubling times of spleen plaque-forming ceils resulting from 
immunization with higher antigen doses or adjuvant treatment 
Cycle times measured 3 days after immunization were compared with dou- 
bling times of spleen plaque-forming cells in the following experiment. 30 rats 
were immunized with 5 X  10  ~ sheep erythrocytes; 30 rats were immunized with 
109 sheep erythrocytes and adjuvant. Five rats in each immunized group were 
I The numbers in parentheses are means of logarithmically transformed data 4- the stand- 
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killed 2, 3, and 4 days after immunization.  On the 3rd day, additional rats in 
each immunized group were injected with colchicine,  1.3 mg/kg, 2.5,  5.0,  or 
7.0 hr before sacrifice 
The  results  are presented  in Tables II  and  HI. The  extent  of drug  sup- 
pression was a  function of the duration  of drug treatment  and  the immuni- 
zation procedure.  In similarly  immunized rats,  cycle times were comparable 
for the various intervals  of drug  treatment.  The mean cycle time  of 7.7 hr 
for plaque-forming ceils in animals immunized with the low antigen dose was 
somewhat shorter than the mean doubling time of 9.2 hr. The mean cycle time 
of 6.4 hr for spleen plaque-forming  cells in animals  immunized with the higher 
dose of antigen  and adjuvant was somewhat longer  than  the  mean doubling 
time of 5.8 hr. 
Drug reduction of plaque-forming cells was compared on various days after 
immunization in the following experiment. 30 rats were immunized with 5 X  107 
sheep erythrocytes, and 30 with 109 sheep erythrocytes and adjuvant. 10 rats 
from each group were killed 2, 3, and 4 days after immunization.  On each day, 
the numbers of spleen plaque-forming cells in five animals given colchicine 5 hr 
before sacrifice  were  compared  with  the  numbers  of spleen  plaque-forming 
cells of five similarly  immunized rats that received no colchicine. 
The results are presented in Tables IV and V. For similarly immunized rats, 
drug  reduction  of numbers  of  spleen  plaque-forming  cells  was  remarkably 
constant 2,  3,  and  4 days after immunization,  although  numbers of plaque- 
forming cells increased enormously during  this  time.  Thus,  the effect of the 
drug was independent of the numbers of plaque-forming  cells in spleens but 
was dependent on the method of immunization.  Cell cycle times calculated 
from drug reduction ranged from 8.1 to 10.4 hr in rats immunized with 5 X  107 
sheep erythrocytes and 5.5 to 5.8 hr in rats immunized with 10  ~ sheep erythro- 
cytes and adjuvant. The mean cycle times and mean doubling times from days 
2 to 4 were comparable in similarly immunized animals. 
The  results  for non-drug-treated,  similarly  immunized  rats,  presented  in 
Tables II and IV, were combined; mean cell doubling times calculated from the 
increase  in  spleen  plaque-forming  cells  occurring  between days  2  to  4  are 
presented in Table VI. Also, in these two experiments, additional rats in both 
immunized groups were injected with  colchicine  5 hr before sacrifice  on  the 
3rd day. Mean cycle times estimated from the combined results are also pre- 
sented in Table VI. The cell cycle and doubling times are again in good agree- 
ment,  particularly  for  animals  immunized  with  109 sheep  erythrocytes  and 
adjuvant. 
The following observations provide more direct support for the assumption 
that the drugs reduced the numbers of plaque-forming cells by blocking such 
cells in metaphase. 
Effect of Velban on Mouse Spleen Cells Immunized in Vitro witk Skeep Erytkro- ROWLEY,  I~ITCH,  MOSIER, SOLLIDAY, COPPLESON, BROWN  993 
cy/es.--Dispersed normal spleen cells were cultured in vitro with sheep eryth- 
rocytes. The early kinetics and magnitude of the plaque-forming cell response 
closely parallels that observed in vivo (17,  18).  Similar results have been ob- 
tained in  this laboratory with  the  additional finding that  two functionally 
different spleen cell populations are apparently required for in vitro induction 
of the immune response (19). One population consists of larger phagocytic ceils 
or macrophages that adhere to plastic; the second population consists of smaller 
cells that do not adhere to plastic during short culture periods and are mor- 
phologicaUy lymphocytes. The following observations suggest that close physi- 
cal interaction between macrophages and lymphocytes continues during the in 
vitro immune response. 
TABLE  VI 
Comparison of Cell Cyde and Cell Doubling Times* 
Immunization  Cell cycle time:~  Cell doubling time§ 
5 X  I0  T  SRBC  7.4 (5.7-17)  8.8 (7.8-10.2) 
10  9  SRBC -{-  adjuvant  5.6  (5.3-6.5)  5.6  (5.1--6.0) 
* Selected data from Tables II and IV combined. 
The cell cycle time on the 3rd day estimated from the extent of suppression of plaque- 
forming cells produced by 5 hr of colchicine treatment using the method outlined in the 
Appendix. The numbers in parentheses represent the approximate 95% confidence  limits. 
§ Cell doubling times estimated from the numbers of plaque-forming cells in spleens of 
all ~imilarly  immunized non-colchicine-treated rats 2, 3, and 4 days after immunization, 
using standard methods  outlined in the Appendix. The numbers in parentheses represent the 
95% confidence  limits. 
Cultured mouse spleen cells were collected 4 days after in vitro immuniza- 
tion; the harvesting of cultured cells was done with as little mechanical agita- 
tion of the cell suspension as possible. Plates for determining numbers of plaque- 
forming cells and stained smears were prepared from the suspension before and 
after 30 sec agitation on a vortex mixer. Mechanical agitation of the suspension 
increased from 4 to 38 the number of plaques produced per 10  e cells initiany 
cultured. Most plaques  produced by nondispersed cells contained a  central 
cluster of cells (Fig. 1); stained smears showed that most of the clusters con- 
sisted of numerous lymphocytes surrounding one or more large mononuclear 
cells.  Each plaque produced by the mechanically dispersed cells  contained a 
single centrally located cell. Microscopic examination of suspensions confirmed 
that mechanical agitation had  dispersed  the  cells;  in  addition, microscopic 
examination of cultures before harvesting showed clusters of cells in the culture 
dishes, indicating that clusters do not result from aggregation of cells during 
or after harvesting. In three other experiments of similar design, mechanical 994  ANTIBODY-FORMING CELLS  AND  EARLY  IMMUNE  P.-ESPONSE 
dispersion of the cultured  cells increased the number of plaques by 9-fold or 
more, indicating that most plaque-forming cells are in dusters. 
Addition of Velban to cultures blocked many cells in metaphase and reduced 
the number of plaque-forming cells as shown in the following experiments. On 
the 4th day of culture  of in vitro immunized spleen  cells, Velban diluted  in 
balanced salt solution was added to give a concentration of 10  -6 g/ml of culture. 
The salt solution alone was added to control cultures. Cultures were harvested 
6  hr  later.  Before mechanically dispersing  the  cells,  samples were taken for 
smears. These samples were treated briefly with hypotonic KC1, fixed in acetic 
acid-ethanol, spread on slides in 55 % methanol/45 % acetic acid, air-dried, and 
stained. The remainder of the sample were mechanically dispersed and plates 
TABLE VII 
Cycle Times for Pl~ue-Formlng Cells of In Vitro Immunized Mouse Spleen Cells 
Exp. 1  Exp. 2  Exp. 3 
Velban 
treatment*  Plaque  ~'- ~  Cell cycle  Plaque-  Cell cycle  Plaque-  Cell cycle 
forming cells~  tlme§  forming  cells~:  time§  forming cells:~  time§ 
hr  hr  hr  hr 
None  65  --  41  --  132  -- 
3  35  8.8  20  7.6  82  7.4 
6  16  8.0  7  7.1  15  7.1 
* Cultures, 4 days after in vitro immunization, were treated with Velban 3 or 6 he before 
harvesting. 
:~ Plaque-forming cells are recorded as the number per 10  6 spleen cells initially cultured. 
§ The cell cycle time was calculated using the model presented in the Appendix. The 
corresponding doubling times  calculated from the increase in plaque-forming cells from 
days  2 to 4 for Experiments 1 to 3 were 7.5, 8.4, and 6.5 hr respectively. 
were prepared to determine the total numbers of plaque-forming cells in drug- 
treated  and  control  cultures.  In  non-Velban-treated  cultures,  about  1%  of 
ceils were in metaphase; the per cent of cells in metaphase was not discernibly 
greater in clusters of ceils. In marked contrast, about 10% of all cells in cultures 
treated with Velban for 6 hr were in metaphase, and 20-80% of ceils in clusters 
were in metaphase. Fig. 2 shows a  small cluster of 11  cells,  4 of which are in 
metaphase. Velban treatment for 6 hr reduced from 61 to 13 the total number 
of plaque-forming ceils per  106  spleen  ceils initially  cultured.  The  cell cycle 
time based on Velban suppression was 8.2 hr. 
In three other experiments, cultures were treated with Velban 4 days after 
in vitro immunization. The numbers of plaque-forming ceils in cultures treated 
with the drug for 3 or 6 hr were compared with the numbers in control cultures. 
The reduction in plaque-forming ceils was directly proportional to the duration 
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Velban treatment for 3 or 6 hr differed only slightly, and the cycle times cor- 
responded  quite well  with doubling  times calculated from  the  exponential 
increase in plaque-formlng cells (Table VII). 
DISCUSSION 
The use of Velban or colchicine to estimate cell cycle times in these experi- 
ments was based on the premise  that cells blocked  in mitosis  do not release 
sufficient antibody to be identified,  but that release of antibody by cells in 
interphase is not affected by the drugs. The first assumption is consistent with 
observations  that amino acid incorporation  into protein is markedly decreased 
in other types of cells blocked in metaphase by colchicine (20), possibly as a 
result of disaggregation  of polyribosomes  (21). Many observers  have found 
occasional (< 1%)  cells in the centers  of plaques  in mitosis, but mitosis may 
have occurred in culture after release of antibody, as has been reported recently 
(13).  However,  we  have observed  no plaque-forming  cells in mitosis when 
cells were  obtained from animals treated with Velban  or colchicine, though 
cells in mitosis were evident in stained smears  of spleen cells obtained from 
such animals.  Several  observations  support the second assumption,  i.e.,  that 
neither drug affects release of antibody by cells in interphase.  The distribution 
of size of plaques produced by spleen cells from immunized rats was the same 
whether the cells were obtained from rats treated with Velban,  or  colchicine, 
or were  from untreated rats.  Presumably, the drugs did not produce their 
effects by causing  progressive  diminution of antibody synthesis and by this 
mechanism cause  reduction in  numbers  of detectable plaque-forming  cells. 
Very large doses of Velban or colchicine given 10-15 rain before sacrifice or very 
high concentrations of the drugs added to the culture medium did not reduce 
numbers of plaque-forming  cells, indicating that the drugs are not directly 
toxic to these cells. The extent of reduction was directly proportional to the 
duration of drug treatment, so long as the interval between drug administration 
and animal sacrifice was less than the calculated cell cycle time. The drug effect 
was independent of the number of plaque-forming  cells in spleens. It seems 
more reasonable to assume, therefore,  that these findings are the result of the 
well-known action of colchicine or Velban to arrest cells in metaphase, than to 
assume  that  these  drugs  have  some  other  time-dependent,  antigen-dose- 
dependent toxicity for plaque-forming cells. 
Velban has been used to measure cell cycle times of tumor cells in a model 
very similar to the one described here (22). Inhibition of plating efficiency of 
tumor cells was proportional to the duration of treatment with the drug; cell 
cycle times estimated by this method agreed well with in vivo methods. It is 
of interest that in this model, Velban treatment of cells for a complete estimated 
cell cycle time abolished the capacity of only 90-95 % of tumor cells to grow in 
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exceeded 95 %.  It is not known why Velban  or colchicine treatment for an 
estimated cell cycle time or longer does not abolish all plaques. The calculated 
cycle times represent the mean of a  range of cycle times; the frequency dis- 
tribution of cycle times has not been determined. The 5-10% of cells surviving 
the effects of the drug for the length of a mean cycle time may represent the 
tail of distribution of cycle times, which could have a marked degree of skew- 
ness. In any event, the tumor cell model indicates that the phenomenon is not 
peculiar to antibody-forming cells. 
Using  a  hot pulse labeling technique with spleen  cell  cultures immunized 
in vitro, Dutton and Mishell concluded that essentially all antibody-forming 
cells appearing in cultures could arise by cell division (23).  We arrive at the 
same conclusion using Velban in spleen cell cultures immunized in vitro. Most 
plaque-forming cells in culture are aggregated in clusters. In cultures treated 
with Velban for 6 hr, many of the cells  in clusters were in metaphase; also, 
Velban caused a marked reduction in the total number of plaque-forming cells. 
These  observations support  the premise  that  the drug  caused reduction  of 
plaque-forming cells by arresting these cells in metaphase. 
It might be argued that plaque-forming cells arise from an exponential rate 
of conversion from some other population of cells which had not previously 
produced antibody. In such a model, it might be expected that mitotic block- 
ing agents would interfere with the continued conversion of cells solely by pre- 
venting  multiplication  of  the  precursor  cells.  Plaque-forming  cells  already 
present would  not be  affected by  the mitotic blocking  agents.  Even  if  all 
plaque-forming cells  arose by such conversion from a  cell population with a 
cell cycle time as short as 5 hr the maximum possible suppression by treatment 
with a mitotic blocking agent for 5 hr would be 50%. The data presented here 
are not consistent with such a model. 
Recruitment or continued activation of potential antibody-producing cells 
was  assumed  to have  occurred during  the  early primary immune response, 
because generation times as short as 5.4 or 6.1 hr had not been reported for 
immunocompetent or other mammalian cells  (14).  This general argument for 
recruitment of cells, based solely on an assumed maximum rate for division of 
mammalian ceils, is invalidated by observations that one population of lympho- 
cytes in calf thoracic duct lymph has a cell cycle time of 5.5-6.0 hr (24,  25). 
Adjuvants might cause recruitment of additional responding cells,  but the 
present findings provide no support for this possibility. The number of spleen 
plaque.forming cells is equivalent 24 hr after immunization whether animals 
were immunized with antigen alone or antigen and adjuvant. When adjuvant 
was given 1 day after immunization, enhancement 2, 3, and 4 days after im- 
munization was almost as great as when adjuvant was given at the time of 
immunization; thus, enhancement cannot be accounted for by assuming ap- 
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immunization. If appreciable  recruitment of cells occurred  more than 1 day 
after adjuvant was given, this would result in an increased slope of the logw 
normal plot Of the plaque-forming  cell response  beginning  when additional 
cells entered the population of already responding  cells. No such upward in- 
flexions have been observed. 
It might be argued that the plaque-forming  cell technique measures,  at a 
point in time, the number of cells capable  of synthesizing  and releasing suffi- 
cient antibody to produce detectable plaques  of lysis.  If adjuvant had  the 
effect of increasing  the amount of antibody synthesized or released by cells, 
then this effect would result in increased  numbers of cells that could be enu- 
merated by the plaque-forming cell technique.  Adjuvant enhanced the plaque- 
forming cell response  to a  greater extent than it enhanced serum antibody 
titers. This discrepancy between adjuvant enhancement of the responses might 
be accounted for if the amount of antibody synthesized by a  cell in vivo is 
proportional to the length of interphase.  Possibly,  cells dividing every 5 hr 
synthesize less antibody during each cell generation than cells dividing every 
7 or 9 hr. In any event, the data do not support the suggestion that individual 
cells from adjuvant treated animals synthesize more antibody. 
The increased responses produced by increased doses of antigen or adjuvant 
are apparently the result of increased rates of division of responding cells. This 
is indicated not only by steeper  slopes of log10 normal plots of responses, but 
also by shorter cell cycle  times obtained when mitotic blocking  agents are 
used.  Admittedly, our  experiments  are  not sufficiently  accurate  to  exclude 
recruitment of a few additional responding cells, either as a component of the 
continued response to a single dose of antigen or as part of the enhanced  re- 
sponse with adjuvant. Our findings, however,  are definitely contrary to those 
of Sterzl  and Tannenberg who concluded  on  the basis  of radioautographic 
studies that spleen plaque-forming  cells arose in large part from cells that had 
not undergone recent mitosis (9,  11,  12). We believe  there are technical  and 
conceptual difficulties with these kinds of radioautographic studies; additional 
work will be necessary to resolve inconsistencies between these and the present 
studies. 
Cell doubling times during the early primary response are equivalent by the 
two methods used here. After this phase,  and during the secondary response, 
the kinetics are more complex, first because of the appearance  of cells releasing 
"7S" hemolysin and second because  the numbers of plaque-forming  cells de- 
crease. The decrease may be due to either loss of cells from the spleens by death 
or emigration,  or by change in function of cells. Mitotic blocking agents may 
provide a simple means for obtaining useful information on the kinetics of cell 
responses during the late primary and secondary responses; however, the model 
as presented here, cannot be applied directly to such studies without consider- 
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The results are consistent with a cell selection theory of antibody formation 
(26--29).  Antigenic  stimulation causes  ceils  to  proliferate and  to  synthesize 
antibody; the magnitude of the response is dependent primarily on the rate of 
division of initial responding antibody-producing cells and their progeny. The 
rate of division of antibody-forming cells might be determined by the rate of 
interaction between these ceils and macrophages that have phagocytized anti- 
gen. In the present studies, lymphoid cells,  some of which are undoubtedly 
plaque-forming cells,  were found clustered around macrophages. Anatomical 
connections between lymphocytes and macrophages have been described (30, 
31). Higher antigen doses or an adjuvant might enhance the rate of interaction 
between the two different cell types and by this effect increase the rate of di- 
vision of antibody-forming cells. 
SIJ'M~ARY 
Mitotic blocking agents, colchicine or Velban, were used to estimate cycle 
times of spleen ceils which release hemolysin for sheep erythrocytes (plaque- 
forming cells).  The cells were obtained either from rats immunized with sheep 
erythrocytes or from cultures of mouse spleen cells immunized in vitro with the 
same antigen. 
2, 3, or 4 days after immunization, animals or cell cultures were treated with 
mitotic blocking agents for periods of time ranging from 2.5  to 7 hr; plaque- 
forming cells  were  then  enumerated.  Decreased numbers  of plaque-forming 
cells were found after such treatment. The extent of reduction was a function of 
duration of the drug treatment and the method of immunization, but was in- 
dependent  of  the  time  after immunization. The  evidence presented  is  con- 
sistent with premises that: (a) plaque-forming cells in mitosis do not release 
sufficient antibody to be detected,  (b)  mitotic blocking agents, by arresting 
plaque-forming cells in metaphase, prevent not only detection of these cells but 
also the increase in number of plaque-forming cells which would have resulted 
from cell division, (c) mitotic blocking agents do not affect release of antibody 
by cells in interphase. 
Cell cycle times, based on the extent of reduction of plaque-forming ceils 
per unit time of drug treatment, were estimated using a mathematical model ap- 
propriate for an exponentially increasing population of cells.  Cell cycle times 
estimated using the mitotic blocking agents agreed well with cell doubling times 
calculated from the increase in plaque-forming cells occurring 1-4 days after 
immunization. Increased responses produced by higher antigen doses or treat- 
ment of immunized animals with an adjuvant resulted from an increased rate 
of division of responding cells and their progeny. 
The results are consistent with a cell selection theory of antibody formation. 
Antigenic stimulation causes relatively few cells to proliferate and to synthesize 
antibody; apparently the magnitude of the response  is dependent primarily ROWLEY, I~ITCH, MOSIER, SOLLIDAY, COPPL~ESON~ BROWN  999 
on the rate of division of responding cells. It is suggested on the basis of ob- 
servations of in vitro-~mmunized cell cultures that the rate of division of re- 
sponding cells may be dependent  on the rate of interaction between two cell 
types, both of which are essential for the in vitro plaque-forming cell response. 
It is a pleasure to acknowledge the skilled and devoted assistance of Miss Helga Tremmel 
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APPENDIX 
In the body of the paper,  a  distinction is made between cycle time and  doubling time. 
Doubling time is calculated from the increase in the spleen plaque-forming cells occurring 1-4 
days after immunization; it is the time required for the population to double. It is assumed 
that  the number of plaques formed follows an equation of the form 
y(0  =  k~  bt 
where k is a constant for each experiment, e  is the Naperian constant, b is the logarithm of 
2 divided by the doubling time, and t is time from the beginning of the exponential  response. 
Taking logarithms 
inY(0  =  Ink+hint, 
the logarithms of the observed number of plaques are assumed  to be normally distributed. 
Thus, the situation is that of simple regression analysis. Standard bounds can be calculated 
for the doubling time from the variance of the slope (34). 
The celt cycle time is estimated from the reduction in numbers of observable spleen plaque- 
forming cells produced by mitotic blocking agents.  A mathematical model was constructed 
to estimate cell cycle times and to determine confidence limits of the estimates. The model was 
constructed from the following postulates: 
(a)  The antibody-forming cell population is increasing exponentially. 
(b)  These ceils are completely asynchronous with respect to stage of the mitotic cycles. 
(c)  All cells have a  fixed  cycle time, c, which is the interval between successive mitoses. 
(d)  All cells in mitosis at the moment of administration of the mitotic inhibitor become 
arrested in metaphase.  (All cells that subsequently enter mitosis are also arrested in meta- 
phase.) 
(e) All antibody-producing cells in mitosis, whether arrested in metaphase or not, do not 
form observable plaques. 
(f) There is a  sharply defined point somewhere at the beginning of mitosis when cells no 
longer produce a plaque and a point near the end of mitosis when daughter cells again pro- 
duce observable plaques. The time that the ceils do not produce plaques corresponds roughly 
to the mitotic time and is called a. 
(g) To make analysis tractable, it is assumed that a cell doubles immediately upon entry 
to mitosis. This assumption does not affect the analysis since cells in mitosis are unobservable. 
Let z(0 be the total number of cells present at time t. Postulate (a)  implies that 
z(t)  =  ke  bt  (1) 
for some positive constants  k  and b. Postulate  (c)  implies that  the number of cells present 
doubles in time c, thus e  bc -- 2 or b -- In 2/c. The constant k represents the number of cells 
present at the time that the response to immunization begins. 
By postulates  (a)  and  (g), the number (m) of cells entering mitosis between times tt and 
t2,  (tt  <  t2)  is the same as the number of cells added during this interval, i.e., 
re(t1,  t~)  ffi  z(~)  -  ,.(tO  (2) 
The number of observable plaque-forming cells at time ~ is the total number of cells less 
those in mitosis. The number of cells in mitosis will be twice the number which entered mitosis 
in the interval t -- a to t. Thus, the number of cells observable at time t will be 
y(t)  ffi  z(t)  --  2m(t  --  a,  t)  =  2z(t  --  a)  --  z(t)  =  keht(2e  "-ha  --  1)  (3) 1002  ANTIBODY-FORMING  CELLS AND  EARLY  IMMUNE  RESPONSE 
Assuming that a mitotic blocking agent is injected x hr prior to observation, the effect is 
to render tmobservable all cells in mitosis at the time of injection [i.e., 2m(t  --  x  -  a,  t  --  x) 
cells] and all cells entering mitosis thereafter. Thus, twice the number of cells which entered 
mitosis in the interval t -- x -- a to t are tmobservable. Let w(t,  x)  be the number of observ- 
able cells at time t when mitotic inhibitor was injected x hr prior to t  (where x  <  c -- a  to 
avoid negative numbers being predicted). Then, 
w(t,  x)  =  z(t)  --  2m(t -- x -- a, t)  =  2z(~ -- x -- a)  -- z(0  =  k#t(2e  -'b(~'c'a)  -  1)  (4) 
Inspection of the data showed that the scatter about the mean in the experimental groups 
was grossly dependent on the mean. Logarithmic transformation adequately corrected this 
and was used throughout these calculations to achieve homoscedasticity. 
Having made this transformation, it is assumed that the data are drawn from Gaussian 
distributions and that these distributions have means given by in y(t)  or in w(t, x) and com- 
mon variance. 
To  estimate the parameters, b and  a,  likelihood  methods originated largely by  Fisher 
(32) were used. These methods give the probability density of the possible outcomes of the 
experiment, given the parameters of the model, namely a, c, k, and the variance of the above- 
mentioned Gaussian distributions. 
The principle of maximum likelihood  is to take as estimates of the parameters those values 
which maximize the probability density at the point representing the actual outcome of the 
experiment. Fortunately, it is a property of this model that for fixed values of a and c, it is 
easy to compute the values of the other parameters that maximize the likelihood.  (Details 
will be made available upon request.) A tabulation can be prepared of this likelihood  maxi- 
mized over these parameters against a and ~ and the maximum obtained. 
Asymptotically, twice the negative logarithm of the ratio of the likelihood  at a  nonopti- 
mal parameter point to the maximum likelihood  is distributed as X  ~ with the degrees of free- 
dom equal to the number of estimated parameters (four in this instance). Thus, it is possible 
to set approximate confidence  limits on the estimates. A recent exposition of these methods is 
presented by Rao (33). 
The likelihood function changed very little for different values of c and a if c -- a remained 
the same. Hence, c -- a  is the quantity being estimated in these experiments, given this 
model. Therefore, the results for a  =  0 are those reported in the paper. It is possible to sub- 
stitute appropriate estimates for a. Reported estimate for mitotic time of lymphoid ceils range 
from 15 to 45 min (25, 31). Estimates and confidence  limits may be increased by this amount. 
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FIG. 1.  A  hemolytic plaque produced by a  cluster of cells from a  culture of mouse 
spleen 4 days after in vitro immunization with sheep erythrocytes.  X  200. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 127  PLATE  101 
(Rowley et  al.:  Antibody-forming cells  and  early immune response) PLAZE 102 
FIG. 2.  A  small cluster of ceils  from a  culture of mouse spleen cells 4 days after 
in vitro immunization with sheep erythrocytes. Velban was added to the culture 6 hr 
before harvesting. 4 of 11 cells are in metaphase.  ×  730. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 127  PLATE  102 
(Rowley et  al.:  Antibody-forming cells  and  early  immune response) 